Edwards Lifesciences Corporation $EW Shares Bought by NorthRock Partners LLC

NorthRock Partners LLC grew its stake in shares of Edwards Lifesciences Corporation (NYSE:EWFree Report) by 13.2% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 22,705 shares of the medical research company’s stock after purchasing an additional 2,650 shares during the quarter. NorthRock Partners LLC’s holdings in Edwards Lifesciences were worth $1,776,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Sequoia Financial Advisors LLC lifted its stake in shares of Edwards Lifesciences by 12.6% during the second quarter. Sequoia Financial Advisors LLC now owns 26,461 shares of the medical research company’s stock worth $2,069,000 after purchasing an additional 2,966 shares in the last quarter. MGO One Seven LLC increased its position in shares of Edwards Lifesciences by 9.1% during the second quarter. MGO One Seven LLC now owns 7,266 shares of the medical research company’s stock worth $568,000 after acquiring an additional 604 shares during the last quarter. LRI Investments LLC increased its position in shares of Edwards Lifesciences by 1.0% during the second quarter. LRI Investments LLC now owns 14,971 shares of the medical research company’s stock worth $1,171,000 after acquiring an additional 147 shares during the last quarter. CWM LLC increased its position in shares of Edwards Lifesciences by 24.1% during the second quarter. CWM LLC now owns 40,851 shares of the medical research company’s stock worth $3,195,000 after acquiring an additional 7,935 shares during the last quarter. Finally, OFI Invest Asset Management increased its position in shares of Edwards Lifesciences by 7.0% during the second quarter. OFI Invest Asset Management now owns 339,715 shares of the medical research company’s stock worth $26,569,000 after acquiring an additional 22,282 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $72.94 on Tuesday. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. The business has a 50 day moving average of $77.95 and a two-hundred day moving average of $76.18. Edwards Lifesciences Corporation has a 52 week low of $64.89 and a 52 week high of $83.00. The company has a market cap of $42.82 billion, a P/E ratio of 10.49, a PEG ratio of 3.55 and a beta of 1.05.

Edwards Lifesciences (NYSE:EWGet Free Report) last issued its earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating analysts’ consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same period in the previous year, the firm posted $0.70 earnings per share. Edwards Lifesciences’s quarterly revenue was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on EW. Truist Financial lifted their target price on Edwards Lifesciences from $81.00 to $82.00 and gave the stock a “hold” rating in a research report on Friday, July 25th. Stifel Nicolaus set a $85.00 target price on Edwards Lifesciences and gave the stock a “buy” rating in a research report on Monday, September 22nd. Evercore ISI set a $88.00 target price on Edwards Lifesciences and gave the stock an “outperform” rating in a research report on Tuesday, October 7th. Barclays lifted their target price on Edwards Lifesciences from $90.00 to $95.00 and gave the stock an “overweight” rating in a research report on Friday, July 25th. Finally, Argus raised Edwards Lifesciences to a “strong-buy” rating in a report on Thursday, July 10th. Three research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $87.06.

Check Out Our Latest Research Report on Edwards Lifesciences

Insider Buying and Selling

In other news, VP Daniel J. Lippis sold 4,114 shares of the business’s stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the transaction, the vice president directly owned 22,002 shares in the company, valued at approximately $1,748,278.92. The trade was a 15.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Larry L. Wood sold 8,950 shares of the business’s stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the transaction, the insider owned 206,900 shares of the company’s stock, valued at approximately $16,150,614. This represents a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.34% of the company’s stock.

Edwards Lifesciences Company Profile

(Free Report)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Featured Articles

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EWFree Report).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.